ERBB2 and breast cancer: This is similar to results reported in a recent single centre study that analysed 398 patients with HR+, HER2− metastatic BC by site of disease who had been treated by fulvestrant 500 mg: the median PFS was similar in patients with non-VM and those with lung (without liver) metastases, while patients with liver metastases had significantly worse PFS15.